
The drugmaker’s quarterly profit fell to Rs 878 crore, while its One India business reported growth across several segments.
Cipla’s consolidated net profit fell 35% year over year to Rs 878 crore in Q2FY27. Revenue from operations declined 2.4% to Rs 7,404 crore, according to the company’s exchange filing.
EBITDA fell 26.7% to Rs 1,388 crore, and the margin narrowed to 18.7% from 25% a year earlier. As of 09:08 UTC, Cipla shares traded at Rs 1,345.20, down 0.72% from the previous close.
Cipla said its One India business grew across segments. Its branded prescription business recorded market growth of 15%, while trade generics had strong double-digit quarter-on-quarter growth, supported by portfolio expansion and more than 15 product launches.
North America revenue was $172 million, up $10 million from the previous quarter. Cipla also said the FDA approved gAdvair Diskus, the first dry powder inhaler approved from its US manufacturing network, and that it entered an exclusive partnership with Qilu Pharmaceutical to commercialise a Keytruda biosimilar.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.